{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T05:58:10Z","timestamp":1760853490283},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,29]],"date-time":"2014-11-29T00:00:00Z","timestamp":1417219200000},"content-version":"vor","delay-in-days":2464,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1111\/j.1469-0691.2008.01921.x","type":"journal-article","created":{"date-parts":[[2010,9,13]],"date-time":"2010-09-13T16:05:54Z","timestamp":1284393954000},"page":"10-16","source":"Crossref","is-referenced-by-count":5,"special_numbering":"S2","title":["Treatment of staphylococcal infections with cyclic lipopeptides"],"prefix":"10.1016","volume":"14","author":[{"given":"B.I.","family":"Eisenstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/j.1469-0691.2008.01921.x_bib1","doi-asserted-by":"crossref","first-page":"549","DOI":"10.5694\/j.1326-5377.2004.tb06444.x","article-title":"The dearth of new antibiotic development: why we should be worried and what we can do about it","volume":"181","author":"Charles","year":"2004","journal-title":"Med J Aust"},{"key":"10.1111\/j.1469-0691.2008.01921.x_bib2","series-title":"Cubicin prescribing information","year":"2007"},{"key":"10.1111\/j.1469-0691.2008.01921.x_bib3","series-title":"Cubicin, summary of product characteristics","year":"2006"},{"key":"10.1111\/j.1469-0691.2008.01921.x_bib4","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1001\/jama.298.15.1803","article-title":"Antimicrobial resistance: it's not just for hospitals","volume":"298","author":"Bancroft","year":"2007","journal-title":"JAMA"},{"key":"10.1111\/j.1469-0691.2008.01921.x_bib5","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1001\/jama.298.15.1763","article-title":"Invasive methicillin-resistant Staphylococcus aureus infections in the United States","volume":"298","author":"Klevens","year":"2007","journal-title":"JAMA"},{"issue":"suppl 1","key":"10.1111\/j.1469-0691.2008.01921.x_bib6","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1086\/491710","article-title":"Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal\/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains","volume":"42","author":"Jones","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.01921.x_bib7","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/jac\/dkm258","article-title":"Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant Saureus (MRSA) blood isolates from 2001\u201305","volume":"60","author":"Steinkraus","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2008.01921.x_bib8","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1128\/JCM.01388-06","article-title":"Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period","volume":"44","author":"Wang","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1111\/j.1469-0691.2008.01921.x_bib9","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.chembiol.2004.04.020","article-title":"Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin","volume":"11","author":"Jung","year":"2004","journal-title":"Chem Biol"},{"key":"10.1111\/j.1469-0691.2008.01921.x_bib10","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1128\/AAC.47.8.2538-2544.2003","article-title":"Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus","volume":"47","author":"Silverman","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2008.01921.x_bib11","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1128\/AAC.35.11.2282","article-title":"Daptomycin disrupts membrane potential in growing Staphylococcus aureus","volume":"35","author":"Alborn","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2008.01921.x_bib12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0196-4399(02)80007-1","article-title":"Daptomycin: a novel lipopeptide antibiotic","volume":"24","author":"Thorne","year":"2002","journal-title":"Clin Microbiol Newslett"},{"key":"10.1111\/j.1469-0691.2008.01921.x_bib13","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1128\/AAC.01559-05","article-title":"Diminished macrophage inflammatory response to Staphylococcus aureus isolates exposed to daptomycin versus vancomycin or oxacillin","volume":"50","author":"English","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 2","key":"10.1111\/j.1469-0691.2008.01921.x_bib14","first-page":"ii37","article-title":"Complicated infections of skin and skin structures: when the infection is more than skin deep","volume":"53","author":"DiNubile","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2008.01921.x_bib15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1586\/14787210.5.2.177","article-title":"Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections","volume":"5","author":"Kanafani","year":"2007","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1111\/j.1469-0691.2008.01921.x_bib16","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1128\/AAC.49.7.2735-2745.2005","article-title":"Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations","volume":"49","author":"Tsuji","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2008.01921.x_bib17","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1128\/AAC.45.6.1799-1802.2001","article-title":"Resistance studies with daptomycin","volume":"45","author":"Silverman","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 1","key":"10.1111\/j.1469-0691.2008.01921.x_bib18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1469-0691.2006.01342.x","article-title":"The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria","volume":"12","author":"Rybak","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"10.1111\/j.1469-0691.2008.01921.x_bib19","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1128\/AAC.00738-06","article-title":"Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria","volume":"51","author":"Mortin","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 4","key":"10.1111\/j.1469-0691.2008.01921.x_bib20","first-page":"1581","article-title":"In vitro bactericidal activity of daptomycin against Staphylococcus aureus and Enterococcus spp.: comparison with vancomycin, teicoplanin and linezolid","volume":"12","author":"Drugeon","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"10.1111\/j.1469-0691.2008.01921.x_bib21","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1086\/420818","article-title":"The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections","volume":"38","author":"Arbeit","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.01921.x_bib22","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1111\/j.1469-0691.2008.01921.x_bib23","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/jac\/dkg466","article-title":"Managing skin and soft tissue infections: expert panel recommendations on key decision points","volume":"52","author":"Eron","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2008.01921.x_bib24","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1086\/497143","article-title":"Practice guidelines for the diagnosis and management of skin and soft-tissue infections","volume":"41","author":"Stevens","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.01921.x_bib25","series-title":"European Public Assessment Report for Cubicin","year":"2006"},{"key":"10.1111\/j.1469-0691.2008.01921.x_bib26","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1128\/AAC.44.11.2948-2953.2000","article-title":"Once-daily dosing in dogs optimizes daptomycin safety","volume":"44","author":"Oleson","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2008.01921.x_bib27","series-title":"Mandell, Douglas and Bennett's principles and practice of infectious diseases","first-page":"906","article-title":"Sepsis, severe sepsis and septic shock","author":"Munford","year":"2005"},{"key":"10.1111\/j.1469-0691.2008.01921.x_bib28","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1128\/CMR.10.3.444","article-title":"Update on detection of bacteremia and fungemia","volume":"10","author":"Reimer","year":"1997","journal-title":"Clin Microbiol Rev"},{"key":"10.1111\/j.1469-0691.2008.01921.x_bib29","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0733-8651(03)00030-4","article-title":"Fowler VG Jr. Staphylococcus aureus bacteremia and endocarditis","volume":"21","author":"Petti","year":"2003","journal-title":"Cardiol Clin"},{"key":"10.1111\/j.1469-0691.2008.01921.x_bib30","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1001\/archinte.163.17.2066","article-title":"Clinical identifiers of complicated Staphylococcus aureus bacteremia","volume":"163","author":"Fowler","year":"2003","journal-title":"Arch Intern Med"},{"issue":"suppl 2","key":"10.1111\/j.1469-0691.2008.01921.x_bib31","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1111\/j.1444-0903.2005.00977.x","article-title":"Diagnosis and management of Staphylococcus aureus bacteraemia","volume":"35","author":"Mitchell","year":"2005","journal-title":"Intern Med J"},{"key":"10.1111\/j.1469-0691.2008.01921.x_bib32","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1086\/345476","article-title":"Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis","volume":"36","author":"Cosgrove","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.01921.x_bib33","doi-asserted-by":"crossref","first-page":"264","DOI":"10.5694\/j.1326-5377.2001.tb143562.x","article-title":"Risk of death from methicillin-resistant Staphylococcus aureus bacteraemia: a meta-analysis","volume":"175","author":"Whitby","year":"2001","journal-title":"Med J Aust"},{"key":"10.1111\/j.1469-0691.2008.01921.x_bib34","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1086\/502522","article-title":"The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges","volume":"26","author":"Cosgrove","year":"2005","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1111\/j.1469-0691.2008.01921.x_bib35","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1086\/375057","article-title":"Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia","volume":"36","author":"Lodise","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.01921.x_bib36","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1128\/JCM.42.6.2398-2402.2004","article-title":"Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"42","author":"Sakoulas","year":"2004","journal-title":"J Clin Microbiol"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14609241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14609241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T15:13:31Z","timestamp":1591888411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X14609241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":36,"alternative-id":["S1198743X14609241"],"URL":"https:\/\/doi.org\/10.1111\/j.1469-0691.2008.01921.x","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}